Candin achieved a 45.4% durable clearance rate for the treated wart, nearly doubling the 23.4% clearance rate observed in the placebo group. Topline data were announced from a completed phase 3 trial ...
SAN DIEGO--(BUSINESS WIRE)--Nielsen BioSciences, Inc. (“Nielsen”), a privately-held, San Diego-based biopharmaceutical company, announced the final patient has been successfully enrolled in CFW-3A – A ...
Warts are one of the most common skin disorders worldwide. They can also be among the most challenging to treat. "Warts are stubborn. They often take months to resolve and may involve multiple ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results